Isavuconazonium Sulfate

硫酸艾沙康唑

Report date: 2026/05/26 20:00:28
NMEQIDP

Base Information

Drug NameIsavuconazonium Sulfate
Drug Alias Name艾沙康唑硫酸盐Isavuconazonium sulphateIsavuconazole艾沙康唑硫酸酯爱沙康唑硫酸zh +[14] 
ClassificationSmall molecules > Heterocyclic drugs > Antifungals
Mechanisms of ActionCytochrome P450 51 inhibitors
TargetsCytochrome P450 51
Therapy Area/IndicationsNeutropeniaMyelodysplastic SyndromesRenal Insufficiency +[12] 
Global Approved IndicationsCryptosporidiosisMucormycosisAspergillosis +[4] 
Approved Indications in ChinaMucormycosis
Original Approved Country/TerritoryUnited States
Original Approved Date2015/03/06
Country/TerritoryBelgiumCanadaUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBasilea Pharmaceutica
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma IncAstellas Pharma Global Development IncBasilea Pharmaceutica Deutschland Gmbh +[5] 
Inactive CompaniesBasilea PharmaceuticaThe University Of Texas MD Anderson Cancer CenterJiangsu Aosaikang Pharmaceutical Co Ltd
Active IndicationsCryptosporidiosisMucormycosisAspergillosis +[4] 
Inactive IndicationsNeutropeniaMyelodysplastic SyndromesRenal Insufficiency +[8] 

Other Information

ATC CodeG01AGJ02AC
Related LinksWikipediaDrugBankKEGG